首页> 美国卫生研究院文献>other >Sharing individual patient and parasite-level data through the WorldWide Antimalarial Resistance Network platform: A qualitative case study
【2h】

Sharing individual patient and parasite-level data through the WorldWide Antimalarial Resistance Network platform: A qualitative case study

机译:通过WorldWide抗疟疾抗药性网络平台共享患者和寄生虫水平的个人数据:定性案例研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Increasingly, biomedical researchers are encouraged or required by research funders and journals to share their data, but there's very little guidance on how to do that equitably and usefully, especially in resource-constrained settings. We performed an in-depth case study of one data sharing pioneer: the WorldWide Antimalarial Resistance Network (WWARN). Methods: The case study included a records review, a quantitative analysis of WAARN-related publications, in-depth interviews with 47 people familiar with WWARN, and a witness seminar involving a sub-set of 11 interviewees. Results: WWARN originally aimed to collate clinical, in vitro, pharmacological and molecular data into linked, open-access databases intended to serve as a public resource to guide antimalarial drug treatment policies. Our study describes how WWARN navigated challenging institutional and academic incentive structures, alongside funders' reluctance to invest in capacity building in malaria-endemic countries, which impeded data sharing. The network increased data contributions by focusing on providing free, online tools to improve the quality and efficiency of data collection, and by inviting collaborative authorship on papers addressing policy-relevant questions that could only be answered through pooled analyses. By July 1, 2016, the database included standardised data from 103 molecular studies and 186 clinical trials, representing 135,000 individual patients. Developing the database took longer and cost more than anticipated, and efforts to increase equity for data contributors are on-going. However, analyses of the pooled data have generated new methods and influenced malaria treatment recommendations globally. Despite not achieving the initial goal of real-time surveillance, WWARN has developed strong data governance and curation tools, which are now being adapted relatively quickly for other diseases. Conclusions: To be useful, data sharing requires investment in long-term infrastructure. To be feasible, it requires new incentive structures that favour the generation of reusable knowledge.
机译:背景:研究资助者和期刊越来越鼓励或要求生物医学研究人员共享数据,但是关于如何公平有效地进行生物医学研究的指导却很少,尤其是在资源有限的环境中。我们对一个数据共享先驱者进行了深入的案例研究:全球抗疟疾抵抗网络(WWARN)。方法:该案例研究包括记录审查,对WAARN相关出版物的定量分析,与47位熟悉WWARN的人的深入访谈以及一个由11名受访者组成的见证人研讨会。结果:WWARN最初旨在将临床,体外,药理学和分子数据整理到链接的开放访问数据库中,以用作指导抗疟疾药物治疗政策的公共资源。我们的研究描述了WWARN如何应对具有挑战性的机构和学术激励结构,以及资助者不愿投资于疟疾流行国家的能力建设,这阻碍了数据共享。该网络通过专注于提供免费的在线工具来提高数据收集的质量和效率,并邀请合作作者发表论文来解决政策相关问题,这些问题只能通过汇总分析来回答,从而增加了数据贡献。截至2016年7月1日,该数据库包含来自103个分子研究和186个临床试验的标准化数据,代表135,000名个体患者。开发数据库所花费的时间更长,成本也超出了预期,并且为提高数据贡献者的公平性而进行的工作仍在进行中。但是,对汇总数据的分析产生了新的方法,并在全球范围内影响了疟疾治疗的建议。尽管未达到实时监视的最初目标,但WWARN仍开发了强大的数据治理和管理工具,现在已相对较快地将其用于其他疾病。结论:要有用,数据共享需要对长期基础架构进行投资。为了可行,它需要新的激励结构来支持可重用知识的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号